Our desire to help patients drives everything we do at Visterra.
Clinical trials – research studies testing our therapeutic candidates in healthy subjects and patients – play a critically important part in developing our therapies.
Information about currently recruiting clinical trials of our therapeutic candidates is available below.
INDICATION
PROGRAM
NAME
TRIAL NUMBER
INDICATION
IgA nephropathy
PROGRAM
Sibeprenlimab (VIS649)
NAME
Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue
TRIAL NUMBER
INDICATION
Sjögren Disease
PROGRAM
Sibeprenlimab (VIS649)
NAME
A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren’s (EnVISage)
TRIAL NUMBER
INDICATION
Autoimmune diseases
PROGRAM
VIS171
NAME
A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171 in Participants With Autoimmune Disease(s)
TRIAL NUMBER
